DEXFERRUM (iron dextran) by AbbVie. Approved for anemia. First approved in 1996.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
DEXFERRUM (iron dextran) is an intravenous iron replacement therapy approved in 1996 for the treatment of anemia. It delivers elemental iron directly into the bloodstream via injection to replenish iron stores in patients with iron deficiency. The drug works by providing bioavailable iron needed for hemoglobin synthesis and oxygen transport.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting team consolidation and focus on defended indications or niche positioning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women
Working on DEXFERRUM offers limited career growth opportunity given the product's LOE-approaching status and zero linked job openings. Roles tend to be defensive and maintenance-focused, suitable for mid-career professionals managing mature portfolios rather than high-growth assignments.
Worked on DEXFERRUM at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo